Symcel Appoints Pia van der Zee as Chief Commercial Officer to Spearhead Growth in Emerging Clinical Markets

[STOCKHOLM, OCTOBER 2023] – Symcel, a leading medtech company transforming rapid infection diagnostics and microbial testing, is thrilled to announce the appointment of Pia van der Zee as its new Chief Commercial Officer (CCO). This strategic move comes as Symcel continues to make strides in with the growing adoption of microcalorimetry, with a keen focus on infection detection, diagnostics for severe infections, antimicrobial resistance and sterility testing for Cell & Gene Therapy products.

Pia brings a wealth of experience to Symcel, having held leadership roles in several sector-leading life science and medtech companies, including Agilent Technologies, Biolamina, 2cureX, and ChemoMetec. Her expertise in bringing technological products to market will be invaluable as Symcel seeks to expand its footprint in key clinical and pharma areas.

In her role as CCO, Pia will be at the forefront of Symcel’s commercial operations. She will play a pivotal role in expanding the company’s market segments, particularly in areas like orthopedic infections, antimicrobial development and biofilm studies, which have already garnered significant interest. Furthermore, Pia will lead Symcel’s foray into emerging markets such as sterility testing for cell therapy and biologics and will be instrumental in the release of innovative new products in the upcoming years.

About the opportunities at Symcel, Pia van der Zee remarked, “Symcel is in a very important growth phase and I am delighted to be part of lifting the company to the next level. Over the years, I have been fortunate enough to make new and innovative solutions the choice of scientists around the world and I am excited to have found the next rising star in Symcel.”

Symcel CEO Jesper Ericsson commented, “We are delighted to welcome Pia to the Symcel family. Her vast experience and proven track record in the life science sector make her the perfect fit to drive our commercial endeavors. We are confident that under her leadership, Symcel will reach new heights and continue to be at the cutting edge of novel biological solutions to some of the world’s greatest health challenges.”

For more information, please contact Ben Libberton.

Follow Symcel on LinkedIn and X for our latest news.

About Symcel
Symcel is leading a new era in metabolic measurements for use in R&D, rapid diagnostics and improved therapies. Symcel provides novel products for real-time detection and analysis of biological activity based on a powerful technique called isothermal microcalorimetry. Their solution is a fast, label-free phenotypic screening technology for direct measurements of cell behavior and drug responses. Symcel was founded by leading authorities in microcalorimetry and the current team at Symcel has extensive experience within the diagnostic and biotech industry.